Teicoplanin CAS:61036-62-2

Teicoplanin is indicated for the treatment of serious infections such as pneumonia, septicemia, bone and joint infections, skin and soft tissue infections, and endocarditis caused by susceptible bacteria. It is administered via intravenous infusion or intramuscular injection, with dosages individualized based on the type and severity of the infection, patient's weight, renal function, and other factors. Due to its long half-life, teicoplanin is usually dosed less frequently than other antibiotics like vancomycin, making it advantageous for certain infections requiring prolonged therapy. Monitoring drug levels and kidney function is essential during treatment to ensure efficacy and prevent toxicity. Patients should be aware of potential side effects of teicoplanin, including gastrointestinal disturbances, skin reactions, and nephrotoxicity. Close monitoring for adverse reactions and regular follow-up with healthcare providers are recommended during teicoplanin therapy. Consultation with a healthcare professional is crucial for appropriate dosing, monitoring, and management of side effects to ensure safe and effective use of teicoplanin in the treatment of bacterial infections.